文献速递血液净化与透析

CONVINCE 试验:高通量血液透析滤过与高通量血液透析在不同临床亚组中的患者报告结局

Patient-Reported Outcomes with High-Volume Hemodiafiltration Versus High-Flux Hemodialysis Across Clinical Subgroups: Results from the CONVINCE Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-10-30

CONVINCE 随机对照试验的预设亚组分析,比较高通量后稀释血液透析滤过(HDF,≥23 L/次)与高通量血液透析(HD)对 8 个 PROMIS 域的影响,中位随访 30 个月,纳入 1211 例有基线及随访 PRO 评估的维持性透析患者。结果显示 PRO 治疗效应在各预设临床亚组间总体一致,无临床意义异质性的证据;少数名义交互作用未校正多重比较,属探索性、假设生成性。

要点

  • 高通量 HDF 与高通量 HD 的 PRO 效应在各预设临床亚组间总体一致。
  • 少数名义交互作用未校正多重比较,不具临床指导意义。
  • 不应依据 PRO 选择或排除患者接受高通量 HDF。

核心结论

  • 预设探索性亚组分析未发现各基线特征间存在有临床意义的治疗效应异质性。
  • 名义交互作用未校正多重比较,应视为假设生成性。
  • 研究结果不应指导基于 PRO 选择或排除患者接受高通量 HDF。

研究设计与样本

  • CONVINCE 多中心随机对照试验的预设亚组分析,比较高通量后稀释 HDF(≥23 L/次)与高通量 HD。
  • 纳入 1360 例随机化参与者中 1211 例有基线及随访 PRO 评估者,中位随访 30 个月。
  • 每季度评估 8 个 PROMIS 域,采用线性混合效应模型分析纵向 PRO 变化及治疗与预设基线特征的交互作用。
  • 预设基线特征包括年龄、性别、糖尿病、心血管疾病、透析龄、血管通路类型和残余尿量。
  • 采用联合模型敏感性分析评估全部 8 个纵向 PROMIS 轨迹及至死亡时间,以处理因死亡导致的信息性脱落。

主要发现

  • PRO 治疗效应在各预设临床亚组间总体一致,无临床意义异质性的证据。
  • 校正基线社会人口学及临床特征的模型显示透析龄与躯体功能(P = 0.03)、年龄与疼痛干扰(P = 0.02)、透析龄与睡眠障碍(P = 0.04)存在名义治疗-亚组交互作用。
  • 考虑死亡信息性脱落的联合模型敏感性分析重现前两项交互作用,并发现血管通路类型与睡眠障碍(P = 0.03)、心血管疾病状态与认知功能(P = 0.05)的名义交互作用。
  • 交互作用幅度 modest(中等偏小),为探索性、未校正多重比较,且未在相关 PROMIS 域中一致观察到。

临床怎么用

  • 临床不应依据患者报告结局选择或排除患者接受高通量 HDF。
  • 亚组交互作用结果仅用于假设生成,不改变总体治疗推荐。

局限性

  • 交互作用分析为探索性、未校正多重比较。
  • 交互作用幅度较小,且未在相关 PROMIS 域中一致观察到。
  • 分析基于有基线及随访 PRO 评估的 1211 例参与者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-volume hemodiafiltration (HDF) improves survival and attenuates decline in selected patient-reported outcome (PRO) domains versus high-flux hemodialysis (HD). Whether benefits differ across clinically relevant subgroups remains uncertain. METHODS: We conducted a prespecified subgroup analysis of the multicenter CONVINCE randomized controlled trial comparing high-volume post-dilution HDF (≥23 L/session) with high-flux HD in adults receiving maintenance dialysis. Eight PROMIS domains were assessed quarterly over a median follow-up of 30 months. Linear mixed-effects models evaluated longitudinal PRO changes and treatment-by-subgroup interactions by prespecified baseline characteristics: age, sex, diabetes, cardiovascular disease, dialysis vintage, vascular access type, and residual urine volume. Joint-model sensitivity analyses of all eight longitudinal PROMIS trajectories and time to death assessed informative dropout due to death. RESULTS: Of 1360 randomized participants, 1211 with baseline and follow-up PRO assessments were included. PRO treatment effects were broadly consistent across prespecified clinical subgroups, without evidence of clinically meaningful heterogeneity. Models adjusted for baseline sociodemographic and clinical characteristics showed nominal treatment-by-subgroup interactions for dialysis vintage and physical function (P = 0.03), age and pain interference (P = 0.02), and dialysis vintage and sleep disturbance (P = 0.04). Joint-model sensitivity analyses accounting for informative dropout due to mortality reproduced the first two interactions and identified nominal interactions for vascular access type and sleep disturbance (P = 0.03) and cardiovascular disease status and cognitive function (P = 0.05). Interactions were modest in magnitude, exploratory, unadjusted for multiple comparisons, and not consistently observed across related PROMIS domains. CONCLUSIONS: This prespecified exploratory subgroup analysis found no convincing evidence of clinically meaningful treatment-effect heterogeneity across baseline characteristics examined. Nominal interactions were unadjusted for multiple comparisons and should be regarded as hypothesis-generating. Findings should not guide selection or exclusion of patients for high-volume HDF based on patient-reported outcomes.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cromm K, Fischer F, Pellegrino G, et al. Patient-Reported Outcomes with High-Volume Hemodiafiltration Versus High-Flux Hemodialysis Across Clinical Subgroups: Results from the CONVINCE Trial. Clin J Am Soc Nephrol. 2026. PMID: 42961497. doi:10.2215/CJN.0000001253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。